mbiomics

Stub active Updated Apr 29, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location Munich, Germany
Founded 2018
Latest Stage Series A
Total Raised €30M
Website https://www.mbiomics.com
Sector
biotech microbiome oncology therapeutics deeptech

About

mbiomics is a Munich-based clinical-stage techbio company developing scalable microbiome-based therapeutics for severe and chronic diseases 12. The lead candidate MBX-116 is being prepared for Phase 1B clinical evaluation in 2027 as an immune checkpoint inhibitor co-therapy in advanced melanoma 12. The April 2026 announcement marks the third closing of the company’s Series A, totaling €30M 12.

Funding History

Date Round Amount Lead Co-investors
2026-04-28 Series A (third closing, €12M extension) €12M MIG Fonds Bayern Kapital 12

What Investors Say

No independently sourced investor quotes found.

What Founders Say

No independently sourced founder quotes found.

Sources

  1. GlobeNewswire, “mbiomics Announces Third Closing of Series A, Reaching €30 Million to Advance Microbiome Therapeutics,” April 28, 2026. https://www.globenewswire.com/news-release/2026/04/28/3282408/0/en/mbiomics-Announces-Third-Closing-of-Series-A-Reaching-30-Million-to-Advance-Microbiome-Therapeutics.html↩↩↩↩

  2. TheNextWeb, “Munich’s mbiomics closes €30M to develop live bacterial product,” April 28, 2026. https://thenextweb.com/news/mbiomics-30m-series-a-microbiome-melanoma↩↩↩↩